These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 28372885)

  • 1. The Cost Differential Between Warfarin Versus Aspirin Treatment After a Fontan Procedure.
    Schilling C; Dalziel K; Iyengar AJ; d'Udekem Y
    Heart Lung Circ; 2017 Aug; 26(8):e44-e47. PubMed ID: 28372885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No difference between aspirin and warfarin after extracardiac Fontan in a propensity score analysis of 475 patients.
    Iyengar AJ; Winlaw DS; Galati JC; Wheaton GR; Gentles TL; Grigg LE; Justo RN; Radford DJ; Attard C; Weintraub RG; Bullock A; Sholler GS; Celermajer DS; d'Udekem Y;
    Eur J Cardiothorac Surg; 2016 Nov; 50(5):980-987. PubMed ID: 27229665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economic costs of routine INR monitoring in infants and children--examining point-of-care devices used within the home setting compared to traditional anticoagulation clinic monitoring.
    Gaw JR; Crowley S; Monagle P; Jones S; Newall F
    Thromb Res; 2013 Jul; 132(1):26-31. PubMed ID: 23746471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of warfarin versus aspirin after Fontan surgery.
    Attard C; Monagle PT; d'Udekem Y; Mackay MT; Briody J; Cordina R; Hassan EB; Simm P; Rice K; Ignjatovic V;
    J Thorac Cardiovasc Surg; 2021 Oct; 162(4):1218-1228.e3. PubMed ID: 33563422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of aspirin and warfarin therapy on thromboembolic events in patients with univentricular hearts and Fontan palliation.
    Potter BJ; Leong-Sit P; Fernandes SM; Feifer A; Mayer JE; Triedman JK; Walsh EP; Landzberg MJ; Khairy P
    Int J Cardiol; 2013 Oct; 168(4):3940-3. PubMed ID: 23870650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic Evaluation of the Combined Use of Warfarin and Low-dose Aspirin Versus Warfarin Alone in Mechanical Valve Prostheses.
    El-Hamamsy MH; Elsisi GH; Eldessouki R; Elmazar MM; Taha AS; Awad BF; Elmansy H
    Appl Health Econ Health Policy; 2016 Aug; 14(4):431-440. PubMed ID: 27028445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hospital Inpatient Costs for Single Ventricle Patients Surviving the Fontan Procedure.
    Huang L; Schilling C; Dalziel KM; Xie S; Celermajer DS; McNeil JJ; Winlaw D; Hornung TS; Radford DJ; Grigg LE; Bullock A; Wheaton GR; Justo RN; Blake J; Bishop R; Du Plessis K; d'Udekem Y
    Am J Cardiol; 2017 Aug; 120(3):467-472. PubMed ID: 28583678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children.
    Monagle P; Cochrane A; Roberts R; Manlhiot C; Weintraub R; Szechtman B; Hughes M; Andrew M; McCrindle BW;
    J Am Coll Cardiol; 2011 Aug; 58(6):645-51. PubMed ID: 21798429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Late Thromboembolic Complications Post-Fontan Procedure in Relation to Different Antithrombotic Regimens: 30-Years' Follow-up Experience.
    Al-Jazairi AS; Al Alshaykh HA; Di Salvo G; De Vol EB; Alhalees ZY
    Ann Pharmacother; 2019 Aug; 53(8):786-793. PubMed ID: 30788973
    [No Abstract]   [Full Text] [Related]  

  • 10. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
    Sarasin FP; Bounameaux H
    Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation.
    Lanitis T; Kongnakorn T; Jacobson L; De Geer A
    Thromb Res; 2014 Aug; 134(2):278-87. PubMed ID: 24935675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hospital costs and cost implications of co-morbid conditions for patients with single ventricle in the period through to Fontan completion.
    Huang L; Dalziel KM; Schilling C; Celermajer DS; McNeil JJ; Winlaw D; Gentles T; Radford DJ; Cheung M; Bullock A; Wheaton GR; Justo RN; Selbie LA; Forsdick V; Du Plessis K; d'Udekem Y
    Int J Cardiol; 2017 Aug; 240():178-182. PubMed ID: 28456482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulation control and cost of monitoring of older patients on chronic warfarin therapy in three settings in North East England.
    Abohelaika S; Kamali F; Avery P; Robinson B; Kesteven P; Wynne H
    Age Ageing; 2014 Sep; 43(5):708-11. PubMed ID: 24947831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.
    Athanasakis K; Boubouchairopoulou N; Karampli E; Tarantilis F; Savvari P; Bilitou A; Kyriopoulos J
    Am J Cardiovasc Drugs; 2017 Apr; 17(2):123-133. PubMed ID: 27882517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Australian and New Zealand Fontan Registry Quality of Life Study: Protocol for a population-based assessment of quality of life among people with a Fontan circulation, their parents, and siblings.
    Marshall KH; d'Udekem Y; Winlaw DS; Dalziel K; Woolfenden SR; Zannino D; Costa DSJ; Bishop R; Celermajer DS; Sholler GF; Kasparian NA
    BMJ Open; 2022 Sep; 12(9):e065726. PubMed ID: 36127092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Medical Costs of Patients With Atrial Fibrillation Unsuitable for Warfarin Treatment With Apixaban or Aspirin Based on AVERROES Trial.
    Amin A; Deitelzweig S; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
    Clin Appl Thromb Hemost; 2015 Apr; 21(3):235-40. PubMed ID: 24108232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Long-Term Management of Children and Adults with a Fontan Circulation: A Systematic Review and Survey of Current Practice in Australia and New Zealand.
    Gnanappa GK; Celermajer DS; Sholler GF; Gentles T; Winlaw D; d'Udekem Y; Ayer J
    Pediatr Cardiol; 2017 Jan; 38(1):56-69. PubMed ID: 27787594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Out-of-range international normalized ratio values and healthcare cost among new warfarin patients with non-valvular atrial fibrillation.
    Nelson WW; Wang L; Baser O; Damaraju CV; Schein JR
    J Med Econ; 2015 May; 18(5):333-40. PubMed ID: 25549062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Fontan epidemic: Population projections from the Australia and New Zealand Fontan Registry.
    Schilling C; Dalziel K; Nunn R; Du Plessis K; Shi WY; Celermajer D; Winlaw D; Weintraub RG; Grigg LE; Radford DJ; Bullock A; Gentles TL; Wheaton GR; Hornung T; Justo RN; d'Udekem Y
    Int J Cardiol; 2016 Sep; 219():14-9. PubMed ID: 27257850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Redefining expectations of long-term survival after the Fontan procedure: twenty-five years of follow-up from the entire population of Australia and New Zealand.
    d'Udekem Y; Iyengar AJ; Galati JC; Forsdick V; Weintraub RG; Wheaton GR; Bullock A; Justo RN; Grigg LE; Sholler GF; Hope S; Radford DJ; Gentles TL; Celermajer DS; Winlaw DS
    Circulation; 2014 Sep; 130(11 Suppl 1):S32-8. PubMed ID: 25200053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.